Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods.

Trial Profile

Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Aug 2015 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018 as per ClinicalTrials.gov record.
    • 07 Aug 2015 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top